alanine has been researched along with Infertility, Male in 7 studies
Alanine: A non-essential amino acid that occurs in high levels in its free state in plasma. It is produced from pyruvate by transamination. It is involved in sugar and acid metabolism, increases IMMUNITY, and provides energy for muscle tissue, BRAIN, and the CENTRAL NERVOUS SYSTEM.
alanine : An alpha-amino acid that consists of propionic acid bearing an amino substituent at position 2.
Infertility, Male: The inability of the male to effect FERTILIZATION of an OVUM after a specified period of unprotected intercourse. Male sterility is permanent infertility.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In a pilot study with 14 HSAN1 patients, L-serine supplementation similarly reduced dSL levels." | 2.76 | Oral L-serine supplementation reduces production of neurotoxic deoxysphingolipids in mice and humans with hereditary sensory autonomic neuropathy type 1. ( Brown, RH; Eichler, FS; Frosch, MP; Garofalo, K; Hornemann, T; Lee, HJ; Penno, A; Schmidt, BP; von Eckardstein, A, 2011) |
| "Prediabetes has been associated with alterations in male reproductive tract, especially in testis and epididymis." | 1.43 | White tea intake prevents prediabetes-induced metabolic dysfunctions in testis and epididymis preserving sperm quality. ( Alves, MG; Casal, S; Dias, TR; Oliveira, PF; Rato, L; Silva, BM, 2016) |
| "He had a complete form of idiopathic hypogonadotropic hypogonadism, with descended testes and severe oligospermia but little response to exogenous gonadotropins." | 1.31 | Clinical phenotype and infertility treatment in a male with hypogonadotropic hypogonadism due to mutations Ala129Asp/Arg262Gln of the gonadotropin-releasing hormone receptor. ( Cohen, DP; Layman, LC; Smith, GD; Xie, J, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (71.43) | 29.6817 |
| 2010's | 2 (28.57) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dias, TR | 1 |
| Alves, MG | 1 |
| Rato, L | 1 |
| Casal, S | 1 |
| Silva, BM | 1 |
| Oliveira, PF | 1 |
| Garofalo, K | 1 |
| Penno, A | 1 |
| Schmidt, BP | 1 |
| Lee, HJ | 1 |
| Frosch, MP | 1 |
| von Eckardstein, A | 1 |
| Brown, RH | 1 |
| Hornemann, T | 1 |
| Eichler, FS | 1 |
| Layman, LC | 1 |
| Cohen, DP | 1 |
| Xie, J | 1 |
| Smith, GD | 1 |
| Maiorino, M | 1 |
| Bosello, V | 1 |
| Ursini, F | 1 |
| Foresta, C | 1 |
| Garolla, A | 1 |
| Scapin, M | 1 |
| Sztajer, H | 1 |
| Flohe, L | 1 |
| Olesen, C | 1 |
| Silber, J | 1 |
| Eiberg, H | 1 |
| Ernst, E | 1 |
| Petersen, K | 1 |
| Lindenberg, S | 1 |
| Tommerup, N | 1 |
| Watanabe, M | 1 |
| Sueoka, K | 1 |
| Sasagawa, I | 1 |
| Nakabayashi, A | 1 |
| Yoshimura, Y | 1 |
| Ogata, T | 1 |
| Tschanter, P | 1 |
| Kostova, E | 1 |
| Luetjens, CM | 1 |
| Cooper, TG | 1 |
| Nieschlag, E | 1 |
| Gromoll, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy of L-Serine in Subjects With Hereditary Sensory Neuropathy Type 1[NCT01733407] | Phase 1/Phase 2 | 18 participants (Actual) | Interventional | 2013-09-30 | Completed | ||
| Tolerability and Efficacy of L-Serine in Patients With Amyotrophic Lateral Sclerosis: A Phase IIa Study[NCT03580616] | Phase 2 | 43 participants (Actual) | Interventional | 2018-10-24 | Terminated (stopped due to Study was terminated by the IRB due to continued noncompliance.) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Plasma levels of the deoxysphingoid lipid 1-deoxy-sphinganine measured by liquid chromatography/mass spectrometry after hydrolyzing the N-acyl and O-linked headgroups (NCT01733407)
Timeframe: 48 Weeks
| Intervention | micromole per liter (Mean) |
|---|---|
| Sugar Pill | 0.338 |
| L-serine | 0.112 |
Plasma levels of the deoxysphingoid lipid 1-deoxy-sphingosine measured by liquid chromatography/mass spectrometry after hydrolyzing the N-acyl and O-linked headgroups (NCT01733407)
Timeframe: 48 weeks
| Intervention | micromole per liter (Mean) |
|---|---|
| Sugar Pill | 0.698 |
| L-serine | 0.337 |
Autonomic Function Testing (AFT) tests the effectiveness of your autonomic nervous system which regulates important functions such as blood pressure, heart rate, and respiration. AFT results are quantified using the composite autonomic severity score scale (CASS) which is a scale from 0 to 10 that is the sum of three sub scores (cardiovagal, adrenergic, and sudomotor). Cardiovagal is scored from 0 to 3, sudomotor is scored from 0 to 3, and adrenergic is scored from 0 to 4. The tests include deep breathing, Valsalva maneuver, head-up tilt, and a sweat test. The three subscores are then summed. This total represents the CASS which classifies autonomic function as normal functioning (total score 0), mild (total score 1-3), moderate (total score 4-6), or severe (total score 7-10). (NCT01733407)
Timeframe: 48 Weeks
| Intervention | scores on a scale (Mean) |
|---|---|
| Sugar Pill | 3.56 |
| L-serine | 2.22 |
The Charcot Marie Tooth Neuropathy Score (CMTNS) is a 0 to 36 point composite scoring assessment that is used to measure disease severity in Charcot Marie Tooth Neuropathy and other sensory and motor neuropathies. The CMTNS is composed of 9 items that evaluate functions related to disease progression. These 9 parameters include reviewing sensory symptoms, motor symptoms (arms and legs), pinprick sensibility, vibration, leg strength, arm strength, and nerve conduction tests. Each item is scored from 0 to 4, with the lower scores representing less severe symptoms and higher scores representing more severe symptoms.The 9 individual item scores are then totaled to provide a global measure of disease severity. For example the lowest possible total score is 0 which represents an asymptomatic individual and the highest score possible is a 36 which represents an individual with severe disease progression. There are sub scores that can be assessed but sub scores were not utilized in this study (NCT01733407)
Timeframe: 48 Weeks
| Intervention | scores on a scale (Mean) |
|---|---|
| Sugar Pill | 25.67 |
| L-serine | 20.22 |
Counts of nerve fibers per unit area in skin biopsies (NCT01733407)
Timeframe: 48 Weeks
| Intervention | nerve fibers per micrometer^2 (Mean) | |
|---|---|---|
| Upper Thigh | Lower Calf | |
| L-serine | 49.56 | 13.89 |
| Sugar Pill | 34.67 | 0.89 |
Evaluates the functioning of electrical conduction of the motor and sensory nerves of the human body. (NCT01733407)
Timeframe: 48 Weeks
| Intervention | microvolts (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Sensrory Right Median Amplitude | Sensory Right Antebrach Amplitude | Sensory Right Superficial Radial Amplitude | Sensory Right Sural Amplitude | Sensory Right Superficial Peroneal Amplitude | Motor Right Median (Wrist) Amplitude | Motor Right Ulnar (Wrist) Amplitude | Motor Right Peroneal EDB (Ankle) Amplitude | Motor Right Peroneal Tib (Below) Amplitude | |
| L-serine | 5.51 | 5.89 | 10.84 | 1.07 | 0.00 | 4.21 | 4.37 | 0.24 | 1.39 |
| Sugar Pill | 1.34 | 2.31 | 4.56 | 0.52 | 0.00 | 3.34 | 2.49 | 0.54 | 0.29 |
1 trial available for alanine and Infertility, Male
| Article | Year |
|---|---|
Oral L-serine supplementation reduces production of neurotoxic deoxysphingolipids in mice and humans with hereditary sensory autonomic neuropathy type 1.
Topics: Administration, Oral; Adult; Aged; Alanine; Animals; Depression, Chemical; Dose-Response Relationshi | 2011 |
Oral L-serine supplementation reduces production of neurotoxic deoxysphingolipids in mice and humans with hereditary sensory autonomic neuropathy type 1.
Topics: Administration, Oral; Adult; Aged; Alanine; Animals; Depression, Chemical; Dose-Response Relationshi | 2011 |
Oral L-serine supplementation reduces production of neurotoxic deoxysphingolipids in mice and humans with hereditary sensory autonomic neuropathy type 1.
Topics: Administration, Oral; Adult; Aged; Alanine; Animals; Depression, Chemical; Dose-Response Relationshi | 2011 |
Oral L-serine supplementation reduces production of neurotoxic deoxysphingolipids in mice and humans with hereditary sensory autonomic neuropathy type 1.
Topics: Administration, Oral; Adult; Aged; Alanine; Animals; Depression, Chemical; Dose-Response Relationshi | 2011 |
6 other studies available for alanine and Infertility, Male
| Article | Year |
|---|---|
White tea intake prevents prediabetes-induced metabolic dysfunctions in testis and epididymis preserving sperm quality.
Topics: Alanine; Animals; Cell Survival; Epididymis; Food Preservation; Functional Food; Glucose Transporter | 2016 |
Clinical phenotype and infertility treatment in a male with hypogonadotropic hypogonadism due to mutations Ala129Asp/Arg262Gln of the gonadotropin-releasing hormone receptor.
Topics: Adult; Alanine; Arginine; Aspartic Acid; Chorionic Gonadotropin; Follicle Stimulating Hormone; Genot | 2002 |
Genetic variations of gpx-4 and male infertility in humans.
Topics: Alanine; Alleles; Amino Acid Substitution; Case-Control Studies; Genetic Variation; Glutathione Pero | 2003 |
Mutational analysis of the human FATE gene in 144 infertile men.
Topics: Adult; Alanine; Amino Acid Sequence; Animals; Arginine; Cysteine; DNA Mutational Analysis; DNA Prime | 2003 |
Association of male infertility with Pro185Ala polymorphism in the aryl hydrocarbon receptor repressor gene: implication for the susceptibility to dioxins.
Topics: Adult; Alanine; Alleles; Basic Helix-Loop-Helix Transcription Factors; Case-Control Studies; Dioxins | 2004 |
No association of the A260G and A386G DAZL single nucleotide polymorphisms with male infertility in a Caucasian population.
Topics: Alanine; Amino Acid Sequence; Base Sequence; Case-Control Studies; Gene Frequency; Genetic Predispos | 2004 |